证券代码：002082 证券简称：万邦德 公告编号：2026-006 万邦德医药控股集团股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 1、会议召开时间 1）现场会议时间：2026年1月28日下午14:00。 2）网络投票时间：通过深圳证券交易所交易系统进行投票的时间为2026年1 月28日上午9:15-9:25，9:30-11:30，下午13:00-15:00；通过深圳证券交易所互 联网系统进行投票的时间为2026年1月28日上午9:15至下午15:00期间的任意时 间。 5、会议召开方式：本次会议采取现场投票表决和网络投票表决相结合的方 式召开。 会议的召集、召开及表决程序符合《公司法》等相关法律法规及部门规章和 《公司章程》等有关规定。 二、会议出席情况 2、会议召开地点：浙江省台州市温岭市城东街道百丈北路28号，公司行政 楼会议室。 3、会议召集人：万邦德医药控股集团股份有限公司（以下简 ...

关 于 国浩律师（杭州）事务所 2026 年第一次临时股东会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 万邦德医药控股集团股份有限公司 国浩律师（杭州）事务所 关 于 万邦德医药控股集团股份有限公司 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二零二六年一月 国浩律师（杭州）事务所 法律意见书 2026 年第一次临时股东会 法律意见书 致：万邦德医药控股集团股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受万邦德医药控股集团股 份有限公司（以下简称"公司"）委托，指派律师出席公司 2026 年第一次临时股 东会（以下简称 ...

Core Viewpoint - The traditional Chinese medicine sector experienced a decline of 0.71% on January 14, with Wanbangde leading the drop, while the Shanghai Composite Index fell by 0.31% and the Shenzhen Component Index rose by 0.56% [1] Group 1: Market Performance - The closing price of Wanbangde was 16.76, down by 3.01%, with a trading volume of 266,800 shares and a transaction amount of 450 million [2] - The top gainers in the traditional Chinese medicine sector included Renhe Pharmaceutical, which closed at 6.32, up by 3.10%, with a trading volume of 925,100 shares and a transaction amount of 579 million [1] - The overall net outflow of main funds in the traditional Chinese medicine sector was 342 million, while retail investors saw a net inflow of 240 million [2] Group 2: Individual Stock Analysis - Renhe Pharmaceutical had a net inflow of 74.86 million from main funds, accounting for 12.92% of its total, while retail investors had a net outflow of 50.46 million [3] - Kunming Pharmaceutical saw a net inflow of 44.97 million from main funds, representing 17.50%, with a net outflow of 28.44 million from retail investors [3] - Yunnan Baiyao had a net inflow of 22.29 million from main funds, which is 3.32% of its total, while retail investors experienced a net outflow of 25.09 million [3]

1月12日晚，万邦德（002082）和海翔药业（002099）双双发布公告，双方同意围绕渐冻症适应症，发 挥各自优势，开展相关合作。 公告显示，1月12日，万邦德全资子公司万邦德制药集团有限公司(下称"万邦德制药")与海翔药业签订 了《创新药合作协议》，致力于通过本次合作，高效推进WP205产品(渐冻症适应症，下同)的研发，最 终实现该产品在全球主要医药市场(包括但不限于中国、美国、日本等)获得用于治疗渐冻症的监管批准 并成功商业化。 双方初期合作，将聚焦于万邦德制药已获孤儿药认定的WP205产品研发和商业化，后续双方还将就万邦 德制药针对melanocortinreceptor(MCR)靶点的小分子环肽激动剂开展原料与制剂等方面的合作。 万邦德制药主要从事现代中药、化学原料药及化学制剂的研发、生产和销售。在治疗肌萎缩侧索硬化 (下称"ALS"，也称渐冻症)领域，万邦德制药布局了自主研发项目WP205产品，已获得美国FDA针对渐 冻症的孤儿药认定(申请号为DRU-2024-10575)，并申报相关制剂专利。此外，该公司还布局了针对 melanocortinreceptor(MCR)靶点的小分子环肽激动剂，矢志 ...

Core Viewpoint - Zhejiang Haixiang Pharmaceutical Co., Ltd. has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical Holdings Group's wholly-owned subsidiary, focusing on the development and commercialization of WP205 for ALS, with plans to expand into MCR-targeted small molecule peptide agonists [1][2]. Cooperation Agreement Details - Haixiang Pharmaceutical will provide a total of 150 million yuan in funding to Wanbangde Pharmaceutical in two phases: 120 million yuan (80%) within five working days of signing, and 30 million yuan (20%) after reaching an agreement with the FDA on the Phase III clinical plan or obtaining conditional market approval in China and the U.S. [1] - In return for its investment, Haixiang will receive 15% of the global commercialization profits from WP205, including 15% of net profits from product sales and third-party licensing [1]. - The agreement includes risk control clauses, allowing Haixiang to terminate the agreement if the Phase III clinical plan is not agreed upon by June 30, 2027, with a full refund of payments plus a 3% annual usage fee [1]. Market Context - ALS has a global average incidence rate of approximately 4.42 cases per 100,000 people, with an average survival period of 3-5 years post-diagnosis, indicating significant unmet clinical needs [2]. - In the U.S., the incidence rate is reported at 4.4 cases per 100,000, highlighting a substantial untapped market potential [2]. Strategic Significance - This collaboration will enhance Haixiang's positioning in the peptide drug sector, leveraging a funding cooperation model to participate in the innovative drug development for neurodegenerative diseases, creating a complementary advantage between industry and research [2]. - The agreement does not constitute a related party transaction or a major asset restructuring, thus not requiring approval from Haixiang's board or shareholders [3].

Group 1 - The core viewpoint of the article is that Wanbangde Pharmaceutical Group has entered into a strategic partnership with Zhejiang Haixiang Pharmaceutical to advance the development and commercialization of the WP205 product, aimed at treating amyotrophic lateral sclerosis (ALS) [1] - The collaboration is formalized through an "Innovative Drug Cooperation Agreement" signed on January 12, 2026, focusing on leveraging each company's strengths for mutual development and strategic win-win outcomes [1] - The initial phase of the partnership will concentrate on the research and commercialization of the WP205 product, which has already received orphan drug designation, with a total investment of 150 million RMB [1] Group 2 - The agreement also includes future collaboration on small molecule cyclic peptide agonists targeting melanocortin receptors (MCR), covering aspects such as raw materials and formulations [1]

证券代码：002082 证券简称：万邦德 公告编号：2026-004 万邦德医药控股集团股份有限公司 关于子公司签订《创新药合作协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示 万邦德制药与海翔药业基于双方优势互补、共同发展，实现战略共赢，签订 了《创新药合作协议》，双方将围绕渐冻症适应症，发挥各自优势，开展相关合 作。双方初期合作将聚焦于万邦德制药已获孤儿药认定的 WP205 产品研发和商 业化，本次合作总金额 1.5 亿元人民币。后续双方还将就万邦德制药针对 melanocortin receptor（MCR）靶点的小分子环肽激动剂开展原料与制剂等方面 的合作。 公司董事会以 9 票同意，0 票弃权，0 票反对的表决结果审议通过了本次交 易。根据《深圳证券交易所股票上市规则》及《公司章程》等相关规定，本次交 易未构成关联交易，也未构成《上市公司重大资产重组管理办法》规定的重大资 产重组。本事项尚需提交公司股东会审议。 二、合作方的基本情况 1.名称：浙江海翔药业股份有限公司 2.统一社会信用代码：913300001482332737 ...

证券代码：002082 证券简称：万邦德 公告编号：2026-005 万邦德医药控股集团股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 4、会议时间： （1）现场会议时间：2026 年 01 月 28 日 14:00:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2026 年 01 月 28 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2026 年 01 月 28 日 9:15 至 15:00 的 任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日 ...

证券代码：002082 证券简称：万邦德 公告编号：2026-003 万邦德医药控股集团股份有限公司 第九届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 董事会同意全资子公司万邦德制药集团有限公司与浙江海翔药业股份有限公 司签订《创新药合作协议》，主要围绕渐冻症适应症领域的在研项目 WP205 展开 合作。 具体内容详见同日披露于巨潮资讯网（www.cninfo.com.cn）等信息披露媒体 的《关于子公司签订<创新药合作协议>的公告》（公告编号：2026-004）。 2.审议通过了《关于召开公司2026年第一次临时股东会的议案》 表决结果：9票同意，0票反对，0票弃权。 同意公司于 2026 年 1 月 28 日(星期三)下午 14:00 在浙江省台州市温岭市城 东街道百丈北路 28 号行政楼会议室召开 2026 年第一次临时股东会，审议本次须 提交股东会批准的议案。 一、董事会会议召开情况 万邦德医药控股集团股份有限公司（以下简称"公司"）第九届董事会第二 十次会议通知于 2026 年 1 月 12 日以邮件、微信等方式发出， ...

Core Viewpoint - The collaboration between Haixiang Pharmaceutical and Wanbangde Pharmaceutical Group focuses on developing innovative drugs for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, leveraging each company's strengths to enhance their market competitiveness [1] Group 1: Collaboration Details - Haixiang Pharmaceutical signed an "Innovative Drug Cooperation Agreement" with Wanbangde Pharmaceutical on January 12, 2023 [1] - The initial collaboration will focus on the WP205 product, which has received orphan drug designation, and its research and commercialization [1] - Future cooperation will involve small molecule cyclic peptide agonists targeting melanocortin receptors (MCR) in areas such as raw materials and formulations [1] Group 2: Strategic Implications - The partnership aims to effectively integrate resources and complement each other's strengths in the innovative drug sector [1] - Haixiang's involvement in the neurodegenerative disease drug development will expand and deepen its presence in the peptide drug field [1] - This collaboration is expected to enhance Haixiang's existing research pipeline and positively impact its innovative development, thereby improving future market competitiveness [1]